score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical	Preclinical		Somatic Variant	MAP2K1	Missense	p.Q56P	0.2955	264.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106						0	6.0	0.3333	0.0703	MAP2K1 p.Q56P (Missense)	0.0	MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	CAMSAP1--COL1A1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				CAMSAP1--COL1A1 Fusion	0.0	MEL-IPI_Pat117		
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat117		
Investigate Actionability	Preclinical			Rearrangement	NF1	Fusion	NF1--RUNX1			0.0	0.0		Investigate Actionability	Azacitidine + Panobinostat	Hypomethylating agent chemotherapy + HDAC inhibition	Combination therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				NF1--RUNX1 Fusion		MEL-IPI_Pat117		
Investigate Actionability	Preclinical			Rearrangement	RUNX1	Fusion	NF1--RUNX1			0.0	0.0		Investigate Actionability	Azacitidine + Panobinostat	Hypomethylating agent chemotherapy + HDAC inhibition	Combination therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				NF1--RUNX1 Fusion		MEL-IPI_Pat117		
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G1037D	0.25	228.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	1.0	0.0	0.0	MET p.G1037D (Missense)	0.0	MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1575L	0.2752	218.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	2.0	0.0	0.0	BRCA1 p.P1575L (Missense)	1.0	MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S835F	0.2126	127.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	1.0	1.0	0.0	PALB2 p.S835F (Missense)	0.0	MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Investigate Actionability	Inferential		Clinical evidence	Rearrangement	CCND1	Fusion	MT-RNR2--CCND1			0.0	0.0		Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122								Investigate Actionability	0.0	In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.	Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5.	https://doi.org/10.1038/ng.2583	0				MT-RNR2--CCND1 Fusion	1.0	MEL-IPI_Pat117		
Investigate Actionability	Inferential		Clinical evidence	Rearrangement	CCND1	Fusion	MALAT1--CCND1			0.0	0.0		Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122								Investigate Actionability	0.0	In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.	Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5.	https://doi.org/10.1038/ng.2583	0				MALAT1--CCND1 Fusion	1.0	MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	TPX2	Fusion	TPX2--TBK1			0.0	0.0																					0				TPX2--TBK1 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	CTNNB1--MLKL			0.0	0.0																					0				CTNNB1--MLKL Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	ASXL1	Fusion	ASXL1--MT-RNR2			0.0	0.0																					0				ASXL1--MT-RNR2 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	IDH2	Fusion	TOMM20--IDH2			0.0	0.0																					0				TOMM20--IDH2 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	PRPF8	Fusion	OXA1L--PRPF8			0.0	0.0																					0				OXA1L--PRPF8 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	JAK1	Fusion	NCAPG--JAK1			0.0	0.0																					0				NCAPG--JAK1 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	SF3B1	Fusion	GFOD2--SF3B1			0.0	0.0																					0				GFOD2--SF3B1 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	PTPN11	Fusion	FASN--PTPN11			0.0	0.0																					0				FASN--PTPN11 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Rearrangement	EZH2	Fusion	EED--EZH2			0.0	0.0																					0				EED--EZH2 Fusion		MEL-IPI_Pat117		
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.P302L	0.3696	46.0	0.0	0.0																					0	0.0	0.0	0.0	NTRK1 p.P302L (Missense)		MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.T103I	0.4872	78.0	0.0	0.0																					0	72.0	0.0	1.0	COL1A1 p.T103I (Missense)		MEL-IPI_Pat117	MEL-IPI_Pat117-Tumor-SM-5X2QU	MEL-IPI_Pat117-Normal-SM-5X2RC
Biologically Relevant				Microsatellite Stability	Supporting variants		NCAPG--JAK1 Fusion, MSH3 p.PPA66del (Deletion)																									0				Supporting variants: NCAPG--JAK1 Fusion, MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat117		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.807																									0				COSMIC Signature (version 2) 7 (81%)		MEL-IPI_Pat117		
